Amylyx Pharmaceuticals, Inc.
AMLX
$13.93
-$0.12-0.85%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -100.08% | -100.32% | -77.06% | -33.22% | 55.71% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.08% | -100.32% | -77.06% | -33.22% | 55.71% |
| Cost of Revenue | -65.51% | -64.71% | 48.88% | 137.06% | 138.03% |
| Gross Profit | -471.35% | -182.01% | -162.22% | -158.98% | -66.97% |
| SG&A Expenses | -63.27% | -64.25% | -39.30% | -15.53% | 14.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -56.64% | -56.96% | 10.90% | 47.63% | 66.18% |
| Operating Income | -27.15% | -155.37% | -852.23% | -3,127.08% | -90.95% |
| Income Before Tax | -15.93% | -234.30% | -656.45% | -4,620.35% | -129.99% |
| Income Tax Expenses | -118.12% | -111.68% | -107.82% | -48.52% | 58.10% |
| Earnings from Continuing Operations | -13.10% | -207.84% | -712.42% | -14,232.14% | -127.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.10% | -207.84% | -712.42% | -14,232.14% | -127.80% |
| EBIT | -27.15% | -155.37% | -852.23% | -3,127.08% | -90.95% |
| EBITDA | -27.64% | -158.26% | -829.45% | -3,574.47% | -91.53% |
| EPS Basic | -2.45% | -197.69% | -705.81% | -42,510.00% | -100.06% |
| Normalized Basic EPS | -20.61% | -163.30% | -744.42% | -10,324.55% | -80.57% |
| EPS Diluted | -2.09% | -189.84% | -734.37% | -16,365.52% | -97.07% |
| Normalized Diluted EPS | -20.07% | -157.54% | -770.79% | -45,072.00% | -79.03% |
| Average Basic Shares Outstanding | 15.08% | 7.59% | 1.41% | 1.73% | 4.97% |
| Average Diluted Shares Outstanding | 13.35% | 4.87% | -2.63% | -1.08% | 3.73% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |